logo
logo
AI Products 

Global Cyclic Heavy Menstrual Bleeding Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

avatar
Uday Kiran
Global Cyclic Heavy Menstrual Bleeding Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

The cyclic heavy menstrual bleeding market size is expected to see strong growth in the next few years. It will grow to $54.27 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing female population, rising prevalence of obesity, increasing access to healthcare, growing popularity of biosimilars, increasing demand for preventive treatments. Major trends in the forecast period include medical advancements, minimally invasive procedures, nutritional approaches, eco-friendly menstrual products.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report 

Segmentation & Regional Insights

The cyclic heavy menstrual bleeding market covered in this report is segmented –

1) By Type: Polymenorrhea; Oligomenorrhea; Metrorrhagia

2) By Treatment Type: Medication; Hormonal Therapy; Surgery

3) By Route of Administration: Oral; Parenteral

4) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users

North America was the largest region in the cyclic menstrual bleeding market in 2023. The regions covered in cyclic heavy menstrual bleeding market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12929&type=smp 

Major Driver Impacting Market Growth

Rising cases of uterine fibroids and polyps are expected to propel the growth of the cyclic heavy menstrual bleeding market going forward. Uterine fibroids and uterine polyps are two common types of noncancerous growths that can develop in the uterus (womb) of women. The treatment for uterine fibroids and polyps reduces blood loss, regulates the menstrual cycle, prevents complications and enhances the emotional well-being of patients suffering from menstrual disorders. For instance, in March 2022, according to Frontiers, a Switzerland-based journal, in the United States, a survey was conducted on 1,346 randomly selected women on the incidence of uterine fibroids between 35 and 49 years screened by self-report, found an incidence of uterine fibroids by age 35 of 60% among African-American women, increasing to >80% by age 50, whereas Caucasian women in this study showed an incidence of 40% by age 35 and almost 70% by age 50. Therefore, rising cases of uterine fibroids and polyps drive the cyclic heavy menstrual bleeding market.

Key Industry Players

Major players in the cyclic heavy menstrual bleeding market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

The cyclic heavy menstrual bleeding market report table of contents includes:

  1. Executive Summary
  2.     Cyclic Heavy Menstrual Bleeding Market Characteristics
  3.     Cyclic Heavy Menstrual Bleeding Market Trends And Strategies
  4.     Cyclic Heavy Menstrual Bleeding Market - Macro Economic Scenario
  5. Global    Cyclic Heavy Menstrual Bleeding Market Size and Growth

.

.

.

  1. Global    Cyclic Heavy Menstrual Bleeding Market Competitive Benchmarking
  2. Global    Cyclic Heavy Menstrual Bleeding Market Competitive Dashboard
  3. Key Mergers And Acquisitions In    Cyclic Heavy Menstrual Bleeding Market
  4.     Cyclic Heavy Menstrual Bleeding Market Future Outlook and Potential Analysis
  5. Appendix

 

Top Major Players :

  • Pfizer Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC




Explore the trending research reports from TBRC:

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company 

Twitter: https://twitter.com/tbrc_info 

Facebook: https://www.facebook.com/TheBusinessResearchCompany 

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ 

Blog: https://blog.tbrc.info/ 

Healthcare Blog: https://healthcareresearchreports.com/ 

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model 

collect
0
avatar
Uday Kiran
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more